Drug Profile
Research programme: cell reprogramming therapies - Vivoscript
Alternative Names: IVR - VivoscriptLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Vivoscript
- Class Cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Diabetes mellitus; Stroke
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 Nov 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 28 Nov 2020 No recent reports of development identified for preclinical development in Stroke in USA